Skip to content

Metabolic

Efinopegdutide

Also called MK-6024, HM12525A

InjectableEvidence BOnce a week
Half-life
120hours
Typical vial
10 / 20mg
Research amounts
5–10mg

per administration

Common schedule
Once a week
Some human use

It has been used in people, but no trial has settled how much or how often.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded150units dialled
Concentration
3.33mg/mL
Volume per draw
1.5mL
Units to dial
150
Doses per cartridge
2

This is 150 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Efinopegdutide describe 510 mg per administration. Descriptive only, not a recommendation.

Multi-day, consistent with once-weekly administration; human figures are not well characterized.

A GLP-1 and glucagon dual receptor agonist studied for weight and liver-fat reduction in phase 2 research. No confirmed dose-ranging publication fixes a subcutaneous schedule for general use, so no schedule table is shown.

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak
1.57× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
25.0days

About five half-lives

Administrations
1/ week

Where these numbers come from

  • Efinopegdutide (MK-6024 / HM12525A) phase 2 programWeekly subcutaneous dosing studied for hepatic fat reduction; the amounts are early-phase, not schedule-establishing.

Next steps